Adage Capital Partners Gp, L.L.C. Cellectis S.A. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $4.71 Million - $6.25 Million	-300,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.21 - $21.02 $2.05 Million - $5.26 Million	-250,000 Reduced 45.45%	300,000 $5.34 Million
Q1 2020 May 15, 2020	SELL	$7.81 - $18.82 $195,250 - $470,500	-25,000 Reduced 4.35%	550,000 $5.06 Million
Q2 2019 Aug 14, 2019	SELL	$14.6 - $20.6 $365,000 - $515,000	-25,000 Reduced 4.17%	575,000 $8.97 Million
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $3.12 Million - $5.68 Million	-200,000 Reduced 25.0%	600,000 $9.99 Million
Q3 2018 Nov 14, 2018	SELL	$25.99 - $30.6 $1.32 Million - $1.55 Million	-50,746 Reduced 5.96%	800,000 $22.6 Million
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $23.6 Million - $32.8 Million	850,746 New	850,746 $24.1 Million

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $88.3M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.